Free Trial
NASDAQ:NDRA

ENDRA Life Sciences Q1 2026 Earnings Report

ENDRA Life Sciences logo
$5.05 0.00 (0.00%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$5.10 +0.04 (+0.89%)
As of 05/15/2026 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ENDRA Life Sciences EPS Results

Actual EPS
-$1.09
Consensus EPS
-$1.23
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

ENDRA Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ENDRA Life Sciences Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
7:00AM ET

Earnings Documents

ENDRA Life Sciences Earnings Headlines

SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
See More ENDRA Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ENDRA Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ENDRA Life Sciences and other key companies, straight to your email.

About ENDRA Life Sciences

ENDRA Life Sciences (NASDAQ:NDRA), Inc. (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems. Using patented algorithms and specialized hardware, the system captures thermoacoustic signals generated when tissue is exposed to low-power microwave pulses. These signals enable clinicians to visualize temperature distributions during procedures such as radiofrequency ablation, microwave ablation and high-intensity focused ultrasound. The company collaborates with hospitals, academic research centers and medical device partners to conduct preclinical and clinical studies that validate the performance and utility of TAEUS technology.

The company holds a growing portfolio of issued and pending patents across the United States, Europe and Asia, and it is advancing toward broader regulatory clearances and international market entry. ENDRA’s leadership team is led by President and Chief Executive Officer David Kaiss, who brings two decades of experience in medical device development, regulatory affairs and commercialization. Under his direction, the company has expanded its R&D capabilities, strengthened manufacturing partnerships and established key distribution channels to support future product launches.

View ENDRA Life Sciences Profile